Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

by Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M. Robinson, Roopal B. Thakkar, Toshifumi Hibi
Published 2017-07-01

Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn’s disease: results from a randomized trial

by Baili Chen, Xiang Gao, Jie Zhong, Jianlin Ren, Xuan Zhu, Zhanju Liu, Kaichun Wu, Jasmina Kalabic, Zhuqing Yu, Bidan Huang, Nisha Kwatra, Thao Doan, Anne M. Robinson, Min-Hu Chen
Published 2020-07-01

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

by Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson
Published 2016-04-01